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2.8 AÊ Resolution Crystal Structure
of Human TRAIL, a Cytokine
with Selective Antitumor Activity
TNFb in complex with three molecules of the extracellu-
lar domain of TNF-R55 (sTNF-R55) (Banner et al., 1993),
it is reasonable to assume that the trimerization of the
TNFR family members constitutes an initiation of the
transmembrane signaling. Since each of the ligand fam-
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in a highly specific manner with typical dissociation con-Korea
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TRAIL (TNF-related apoptosis inducing ligand), a
newly identified member of the TNF family, is a potentSummary
inducer of apoptosis in different cancer cell lines (Wiley
et al., 1995; Pitti et al., 1996) and is involved in CD41 TTRAIL is a newly identified cytokine belonging to the
cell-mediated and monocyte-induced cytotoxicity (Grif-large tumor necrosis factor (TNF) family. TRAIL is a
fith et al., 1999; Kayagaki et al., 1999). TRAIL acts vianovel molecule inducing apoptosis in a wide variety
receptors that are distinct from FasL and TNF receptorsof tumor cells but not in normal cells. To help in eluci-
(Wiley et al., 1995; Pitti et al., 1996). Two cognate mem-dating its biological roles and designing mutants with
brane-bound receptors for TRAIL, DR4 (death receptor-improved therapeutic potential, we have determined
4) and DR5, have been identified, both of which containthe crystal structure of human TRAIL. The structure
a cytoplasmic death domain and extracellular CRDsreveals that a unique frame insertion of 12±16 amino
(Pan et al., 1997a, 1997b; Sheridan et al., 1997). TRAILacids adopts a salient loop structure penetrating into
has generated a great deal of interest in the field of cellthe receptor-binding site. The loop drastically alters
death because it induces apoptosis in most transformedthe common receptor-binding surface of the TNF fam-
cells and some virally infected cells but not in normalily most likely for the specific recognition of cognate
tissues (Wiley et al., 1995; Pitti et al., 1996). In contrastpartners. A structure-based mutagenesis study dem-
to other members of the TNF family, whose expressiononstrates a critical role of the insertion loop in the
is tightly regulated and only transiently expressed oncytotoxic activity of TRAIL.
activated cells (Griffith and Lynch, 1998), significant lev-
els of TRAIL were detected in a variety of normal human
Introduction
tissues. This broad expression of TRAIL suggested that
the regulation of TRAIL-induced apoptosis be through
The TNF family of cytokines play important roles in regu- restricted receptor expression. Subsequent genomic
lating many biological functions, especially as promi- database analyses led to the finding of two decoy recep-
nent mediators of immune regulation and inflammatory tors of TRAIL, DcR1 (also called TRID, TRAIL-R3, or LIT)
responses (Cosman, 1994; Lotz et al., 1996). More than and DcR2 (also called TRUNDD or TRAIL-R4) (Pan et
a dozen proteins belonging to the TNF family are known, al., 1997b; Sheridan et al., 1997; Mongkolsapaya et al.,
including TNFa, TNFb (known as lymphotoxin or LTa), 1998). Both decoy receptors contain extracellular CRDs,
lymphotoxin-b, 4-1BBL, OX40L, CD27L, CD30L, CD40L, which exhibit significant homology to those of DR4 and
FasL (Apo-1L or CD95L), TRAIL (Apo-2L), and OPGL DR5 (54%±58% sequence identity). However, DcR2
(Cosman, 1994; Lacey et al., 1998). These ligands are contains an incomplete cytoplasmic domain and does
expected to function as a homotrimer as suggested by not mediate apoptosis. DcR1 is even more unique in
the structures of TNFa (Jones et al., 1989), TNFb (Eck that it is devoid of any transmembrane or cytoplasmic
et al., 1992), and CD40L (Karpusas et al., 1995). Trans- residues. Most strikingly, the decoy receptors are ex-
membrane receptors for the TNF family constitute the pressed almost exclusively in normal cells. The decoy
large TNF/NGF (nerve growth factor) receptor (TNFR) receptors should be able to bind TRAIL as a trimer but
superfamily characterized by the pseudorepeats of ex- cannot transmit death signals, or they could interfere
tracellular cysteine-rich domain (CRD) (Bazan, 1993). with the signaling by forming nonfunctional hetero-
TNFs and FasL are important activators of apoptosis in trimeric complexes with the signaling receptors. The
the immune system (Nagata and Golstein, 1995). These formation of the nonsignaling complexes acting as
cytokines trigger the suicide response by binding to their ªdecoysº was hypothesized as the chief mechanism
respective transmembrane receptors, TNF-R55 and Fas determining whether a cell is resistant or sensitive to
(CD95 or Apo-1), respectively, both containing a com- the TRAIL-induced apoptosis (Marsters et al., 1997; Pan
mon cytoplasmic death domain. Given the structure of et al., 1997b; Sheridan et al., 1997; Mongkolsapaya et
al., 1998). However, a more recent analysis did not dem-
onstrate any obvious correlation between the mRNA³To whom correspondence should be addressed (e-mail: bhoh@
postech.ac.kr). expression level of the TRAIL receptors and the level of
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Table 1. Structure Determination and Crystallographic Statistics
Crystal Native K2PtC16 K2HgI4
Resolution (AÊ ) 2.80 3.50 3.50
Rsym (%) 6.3 5.8 4.8
Completeness (F . 1s) 89.6 92.8 95.8
Soaking concentration (mM) 2.0 2.0
Soaking time (days) 3 7
Rscale (%) 12.3 13.9
Sites (No.) 6 4
Phasing power (acent/cent) (0.6/0.7) (0.4/0.6)
Rcullis (%, acen/cent) (0.88/0.74) (0.90/0.86)
Figure of merit 0.47
Refinement (F . 1s)
R factor 20.9 Rmsd bond lengths (AÊ ) 0.008
Rfree 28.2 Rmsd bond angles (degree) 1.662
Number of atoms 3219
Water molecules 0 Most favored regions 80.8%
Metal ion 0 Additional allowed regions 18.3%
Average B factor (AÊ 2) 18.4 Disallowed regions 0.9%
Rsym 5 S|Iobs-Iavg| / S Iobs. Rscale 5 S||FPH|-|FP|| / S|FP|. Rscale 5 S|Fder-Fnat| / SFnat. Phasing power 5 rms(|FH| / E), where E is the residual lack of
closure error. Rcullis 5 S|E| / S||FPH|-|FP||. Figure of merit 5 ,S P(a)eia / S P(a)., where a is the phase and P(a) is the phase probability
distribution. The Rfree was calculated with 5% of the data.
sensitivity to TRAIL in a panel of human tumor cell lines TRAIL and FasL that share the highest sequence homol-
ogy (Figure 1). A TRAIL monomer contains two antiparal-(Griffith and Lynch, 1998). Osteoprotegerin (OPG), which
lel b-pleated sheets that form a b sandwich as a coreinhibits osteoclastogenesis and associated bone re-
scaffold, and interacts with the adjacent subunits in asorption, was suggested to bind to TRAIL and inhibits
head-to-tail fashion to form a bell-shaped homotrimerTRAIL function (Emery et al., 1998). This interaction,
(Figure 2A). One end of the trimer is wider (called ªbot-however, was not observed in another study (Lacey et
tomº) than the other end (called ªtopº). The top of theal., 1998). Potential clinical application of TRAIL in can-
molecule is composed exclusively of highly disorderedcer therapy is being explored. In a very recent study,
loops (residues 193±204 and 231±239). The b strandssystemic administration of a TRAIL variant, containing
A99, A, H, C, and F form the inner b sheet involved ina fused leucine zipper sequence to promote oligomer-
the intersubunit contacts, while the b strands B9, B,ization of protomers, actively suppressed tumor growth
G, D, and E form the outer b sheet (Figure 2A). Thein mice without affecting normal tissues (Walczak et al.,
homotrimers are assembled such that one edge of the1999). Since at least 50% of the tumor cell lines tested so
b sandwich (strands E and F) in each subunit is packedfar appear sensitive to TRAIL-induced cell death (Griffith
against the inner sheet of the neighboring subunit. TRAILand Lynch, 1998), the cytokine may prove useful as
exhibits relatively high content of aromatic residuesa safe cancer therapeutic. So far, TRAIL is the only
(17% of total residues). Eight aromatic residues (His-known molecule that exhibits turmor-selective apopto-
125, Phe-163, Tyr-183, Tyr-185, Tyr-189, Tyr-243, Phe-sis-inducing activity without systemic toxicity in mice.
274, and Phe-278) are present on the surface of theIn order to gain insight into the molecular recognition
inner sheet and provide a hydrophobic platform for theof TRAIL with its receptors and to provide a structural
extensive edge-to-face interactions between adjacentframework for directing various mutagenesis and bio-
subunits.chemical studies for this attractive cytokine, we have
The most unique feature of TRAIL distinguished fromdetermined the three-dimensional structure of human
those of other TNF family members is an insertion ofTRAIL and carried out mutational analyses.
12±16 amino acids (depending on the proteins com-
pared with) near the N-terminal cleavage site (Figure 1).
Results and Discussion The insertion occurs at the AA99 loop that was previously
known to be important for the receptor binding of TNFa
TRAIL Structure and a Novel Insertion Loop and TNFb. The structure of TRAIL reveals a striking
The full-length TRAIL is expressed as a type II membrane AA99 loop structure, which can be best appreciated by
protein that is processed proteolytically to form an extra- comparing with the structures of TNFa, TNFb, and
cellular ligand. The truncated and active recombinant CD40L (Figure 2B), whose structural information is avail-
TRAIL (amino acids 114±281; referred to as TRAIL able among the TNF family members. The amino acid
throughout the text) was obtained and crystallized as insertion in TRAIL does not alter the secondary struc-
described (Cha et al., 1999). The crystal structure of tural elements. Instead, it results in an extraordinarily
TRAIL was determined at 2.8 AÊ resolution by the com- elongated AA99 loop traversing one entire subunit struc-
bined method of molecular replacement (MR) and multi- ture twice, whereas the AA99 loops are substantially
ple isomorphous replacement (MIR) (Table 1). TRAIL shorter in the other three related structures (Figures 2
displays low sequence homology to the other members: and 3). About half of the residues on the AA99 loop of
TRAIL (residues 145±160) sit atop the middle part of the38 out of 168 amino acids are identically conserved in
The Crystal Structure of Human TRAIL
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Figure 1. Sequence Alignments and Second-
ary Structure Assignment
Sequence alignments of the TNF family pro-
teins based on previous reports (Wiley et al.,
1995; Pitti et al., 1996) that are adjusted man-
ually on the basis of the superposition of the
four structures in Figure 2B. In the sequence-
based alignments, seven to ten amino acids
in the middle of the AA99 loop of TRAIL are
matched to those of ten other members. The
comparison of the four structures indicates
that these amino acids should be aligned with
the first part of the AA99 loop of TRAIL, as
they are shown here. The secondary structure
assignment and numbering at the top of the
alignment correspond to TRAIL. Amino acids
identical in six or more family members are
darkly shaded. The lightly shaded box and
open boxes marked on the TRAIL sequence
represent the AA99 loop and the disordered
regions absent in the TRAIL structure, re-
spectively. The asterisks indicate the putative
receptor-binding residues that are identified
on the basis of the TNFb/sTNF-R55 structure.
Aromatic amino acids in TRAIL are high-
lighted with bold and larger letters to indicate
a relatively high content of these residues.
b sandwich and are involved in many favorable interac- interactions, the AA99 loop of TRAIL assumes a distinc-
tive structure in the shape of wrapping the trimeric core.tions (Figure 3), while the other half of the loop (residues
130±144) sits atop the upper part of the molecule and
is involved in much fewer interactions. The middle seg- Receptor-Binding Site
The TRAIL receptors belong to the TNFR family (Pan etment of the loop is a b turn that reaches the DE loop
located at one end of a monomer. The anchoring of al., 1997a, 1997b; Sheridan et al., 1997), and the overall
fold of TRAIL is similar to that of the three members ofresidues 145±160 on the b-stranded platform is achieved
by the extensive interactions between these residues the TNF family (Figure 2B). Therefore, based on numer-
ous studies of TNFa mutants (Van Ostade et al., 1994)and many residues scattered on the b sheets and the
GH loop (Figure 3A). Ile-126, Leu-169, Val-258, Val-260, and the structure of the TNFb/sTNF-R55 complex (Ban-
ner et al., 1993), the receptor-binding site of TRAIL canIle-266, Met-268, and Phe-275 are involved in the hy-
drophobic interactions with Ile-151 and Trp-154 on the be safely assumed to be the three identical clefts be-
tween neighboring subunits. Many TNFa mutants defec-AA99 loop. Glu-178 and Tyr-213 are involved in the polar
interactions with Lys-150 and Lys-145 on the AA99 loop, tive or exhibiting altered affinities in receptor binding
carry mutations in these regions, which, consistently,respectively. Four aromatic residues (Tyr-209, Tyr-211,
Tyr-213, and Phe-257) located on the surface of the are in contact with the receptor molecules in the struc-
ture of the TNFb/sTNF-R55 complex. The loop regionsouter b sheet are clustered and interact with five resi-
dues on the AA99 loop (Lys-145, Ala-146, Leu-147, Gly- at the intersubunit clefts of TRAIL, which should be cru-
cial for the interactions with the cognate receptors, are148, and Lys-150) that are absent in all the other TNF
family members (Figures 1 and 3A). None of the four well defined except for residues 130±132, 137±140, and
157±158. It should be noted that the conformations ofaromatic acids or Glu-178 is a conserved residue. Prob-
ably, they have been selected for the favorable interac- all the loops in the TRAIL structure are affected minimally
by crystal packing interactions since they are mainlytions with the unusually elongated loop. Owing to these
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Figure 2. TRAIL Trimer and Monomer
(A) The ribbon diagram of the TRAIL trimer
shown with each b strand for one subunit
labeled, following the notation of Eck et al.
(1992). In this notation, the loop connecting
the strands A and A99 is named AA99 loop,
and likewise for the other loops. The three
monomers are represented by different col-
ors, and the AA99 loop is shown in green. Dis-
ordered loops at the top of the trimer are not
included.
(B) Stereo view of the superimposed Ca trac-
ing of TRAIL (green), TNFa (yellow), TNFb
(red), and CD40L (violet). The AA99, DE, and
GH loops showing structural differences are
pointed out by arrows in cyan, yellow, and
blue, respectively. The loops are involved in
the binding of the receptor in the TNFb/
sTNF-R55 structure. Unlike the AA99 loop, a
meaningful link is not found between the local
conformational differences and the receptor-
binding properties of the DE and GH loops.
between residues on the b strands. Interestingly, the polar segment composed of Lys-142, Glu-143, Asn-144,
and Lys-145. They are all solvent accessible and contrib-AA99, DE, and GH loops that make major contacts with
the receptor in the structure of the TNFb/sTNFR-55 ute to the electrostatic property of the receptor-binding
sites.complex (Banner et al., 1993) display local structural
differences compared with the three related proteins A structure-based sequence alignment of TRAIL and
TNFb allowed us to map out residues that are potential(Figure 2B).
The salient AA99 loop structure described above signif- candidates interacting with the TRAIL receptors on the
basis of the TNFb/sTNF-R55 complex. As shown in Fig-icantly affects the surface property of the receptor-bind-
ing sites of TRAIL. In the three related structures, the ure 1, only one residue, Asp-267, is conserved among
these residues. Therefore, the receptor-binding sur-AA99 loop is short and partakes in one of the two recep-
tor-binding sites lined by each subunit. In TRAIL, the b faces of the TNF family members are quite different from
each other as can be appreciated by the electrostaticturn of the AA99 loop penetrates into and delineates the
other receptor-binding site across a monomer (Figures potentials of TRAIL and the other three members (data
not shown). The presence of the frame insertion, found2A and 3). As a consequence, the receptor-binding sites
of TRAIL are distinctively deeper grooves (Figure 4B) for the first time in TRAIL, suggests that the replace-
ments of the residues at the receptor-binding sites ofcompared with those of the other three TNF family mem-
bers (data not shown). Remarkably, the b turn is a highly TNF family members may not be sufficient to warrant
The Crystal Structure of Human TRAIL
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Figure 3. The AA99 Loop of TRAIL
(A) Interactions of the AA99 loop along the
surface of TRAIL. The residues on the AA99
and the GH loop are shown in green and
khaki, respectively. The cyan dotted lines
represent polar interactions. (B) The final
2Fo-Fc electron density map contoured at 1s
showing residues 145±155 on the AA99 loop
that interact with the outer b sheet platform.
The orientation of the peptide segment is
roughly perpendicular to that shown in (A) for
clarity. The electron density of this external
loop is weaker than that of the central b
sheets.
specific recognition of cognate partners among the alter the geometric and electrostatic property of the
receptor-binding surface without changing the struc-large receptor family. The loop structure adopted by the
frame insertion is clearly a drastic means employed to tural scaffold.
Immunity
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Figure 4. A Model for TRAIL/sDR4 Complex
(A) Surface representation of the TRAIL trimer
exhibiting a cleft at the interface between
neighboring molecules that fits the sDR4
model (Ca worm representation) with a geo-
metric complementarity. (B) Surface repre-
sentation of the TRAIL trimer (left) and sDR4
(right) with the electrostatic potentials shown.
Positive, neutral, and negative electrostatic
potentials are colored blue, white, and red,
respectively. The same coloring scale is ap-
plied to TRAIL and the sDR4 model. The ori-
entation of TRAIL is the same as in (A), while
the sDR4 model is rotated 1808 along an axis
lying on the figure from the orientation in (A)
to show general electrostatic complementari-
ties between the two. Major contact regions
between TRAIL and the sDR4 model are la-
beled with numbers 1 through 6. The amino
acids responsible for the charged surface of
TRAIL are Lys-142 (region 1), Glu-144 and
Asp-218 (region 2), Lys-224 and partially ex-
posed Asp-269 (region 4), and Asp-267 (re-
gion 5). Although Lys-224 is not defined as a
putative receptor-binding residue in the text
according to the TNFb/sTNF-R55 structure,
it forms an ion bridge with Glu-69 of sDR4
in the TRAIL/sDR4 model. Interestingly, Arg-
207 in CD40L, corresponding to Lys-224 in
TRAIL, is also engaged in a charged interac-
tion with CD40 in a modeling study of the
CD40L/CD40 complex (Singh et al., 1998).
The major contact regions constituted by the
AA99 loop are encircled. The left circle indi-
cates the b turn region of the loop (residues
142±145), and the right circle indicates the
last part of the loop.
Receptor Recognition: Modeling TRAIL/sDR4 (see Experimental Procedures). The model exhibits an
excellent geometric and electrostatic complementarityComplex and Mutagenesis
All the known TRAIL receptors contain two repeats of (Figures 4A and 4B). The significant geometric alteration
of the receptor-binding site caused by the AA99 loop ofextracellular CRDs, whereas the other TNF receptor
family members contain three or more CRDs (Smith et TRAIL compared with that of TNFb was mainly accom-
modated by the torsion angle changes at the connectional., 1994). sTNF-R55 consists of four concatenated
CRDs, each of which in turn contains two modules. In (Gln56) between modules (see Experimental Proce-
dures). The amino acid substitutions in sDR4 comparedthe TNFb/sTNF-R55 structure, the second CRD and the
first module in the third CRD of sTNF-R55 interact heav- with sTNF-R55 (His-93→Asn-64, Tyr-94→Asp-65, Trp-
95→Asn-66, Asn-98→Glu-69, Lys-66→Ser-39, and Gly-ily with TNFb (Banner et al., 1993), and they display a
high sequence similarity particularly to that of sDR4. 69→Asp-40 for the negative electrostatic region; Ala-
50→Asn-23, Ile-73→Arg-44, and Asp-81→Asn-52 for theThe remaining first and fourth CRDs of sTNF-R55 do
not interact with TNFb. Therefore, the three modules positive electrostatic region) are consistent with the op-
posite charge distributions in TRAIL. The substitutedfrom the N terminus of the TRAIL receptors should be
involved in the recognition of TRAIL. A model of TRAIL/ residues in sDR4 are mostly identical or homologous to
the corresponding residues in DR5, DcR1, and DcR2.sDR4 complex was constructed on the basis of the se-
quence alignment and the TNFb/sTNF-R55 structure In the model, the b turn region of the AA99 loop (Figure
The Crystal Structure of Human TRAIL
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Figure 5. Sliced View of TRAIL
The orientation of TRAIL is the same as in
Figure 4. Cavities existing along the central
3-fold axis are in blue. Arrows 1 and 2 indicate
the position of Cys-230 and Tyr-183, respec-
tively. The cysteine residue from each subunit
should be in the reduced form, since the
TRAIL sample for the crystallization con-
tained 1 mM dithiothreitol. The distance be-
tween the sulfur atoms (2.6 AÊ ) and the molec-
ular symmetry restriction indicate that these
residues cannot form disulfide bonds even
in an oxidizing condition. Figures 2 and 3A
were produced using the program MOL-
SCRIPT (Esnouf, 1997), Figure 3B using the
program O (Jones and Kjeldgaard, 1993), and
Figures 4 and 5 using the program GRASP
(Honig and Nicholls, 1995).
4B, regions 1 and 2), the last portion of the AA99 loop small ions to pass (Kagan et al., 1992). Under low pH, the
native structure is thought to undergo a conformational(region 6), the DE loop (region 3), and the GH loop (region
change at the outer part of the molecule into a mem-5 and the central hydrophobic region) are involved in
brane insertion form to result in the ion depletion ofextensive contacts with the receptor. The modeling ex-
the cells. The subunit interactions of TRAIL along theperiment suggests that the built-in flexibility of the TNFR
molecular 3-fold axis are quite different from those offamily members, observed specifically for sTNF-R55, is
the related proteins and leave a hole that is not adequatelikely to play a general and important role in the recogni-
for the passage of ions. Ionic interactions or alternatingtion of cognate TNF family ligands without a need to
ion pair interactions along the central axis observed inchange the common structural scaffold of the receptor
TNFa and TNFb (Eck and Sprang, 1989; Eck et al., 1992)family.
are not present in TRAIL. Instead, from the midway toTo test and validate the model of the complex, we
the bottom of the molecule, a cluster of nine aromaticgenerated TRAIL mutants (D137±152; a deletion of the
residues (Tyr-183, Tyr-243, and Phe-278 from each sub-insertion loop, E144N and E144K on the b turn region
unit) are involved in intimate hydrophobic and hydrogenof the AA99 loop, D218N and D218K on the DE loop, and
bonding interactions forming a tight core of the trimerD267N and D267K on the GH loop). The three target
interface. Cys-230 from each subunit at the top portionresidues are solvent exposed in the TRAIL structure and
of the molecule is engaged in intimate van der Waalsinteract with sDR4 in the model of the complex. The
dispersion interactions with each other perpendicularlethal dose 50 of the wild-type TRAIL is 20 ng/ml when
to the central axis (Figure 5). Therefore, only a very
the cytotoxic activity was measured using Jurkat T cell
narrow see-through hole is present in this region of
as reported (Creasey et al., 1987). In contrast, the D137- TRAIL, suggesting no channel activity associated with
152 and E144K mutants did not show any detectable this cytokine.
activity, and the E144N mutant led to the killing of only For the efficacy test in animal models (Walczak et al.,
24% of the total cells even at 200 ng/ml. The cytotoxic 1999), it was critical to improve the stability of the trimer
activities of the other point mutants were less than 10% structure of TRAIL by addition of a leucine zipper to the
of that of the wild-type. These data demonstrate that N terminus of TRAIL. Consistently, we observed that
the insertion loop is critical for the recognition of the active trimeric TRAIL gradually converts into inactive
TRAIL receptors and support our model in which the form. TRAIL was eluted as virtually a single peak from
AA99 loop (especially, the b turn region), DE loop, and the size exclusion column employed for the protein puri-
GH loops interact heavily with sDR4. Full description of fication (see Experimental Procedures). However, after
the mutagenesis study will be discussed elsewhere. the purified TRAIL was stored for a week at 48C, it was
eluted as two peaks with comparable sizes from the
Other Structural Features of TRAIL same column. While the peak corresponding to the first
TNFa has long been known to exhibit a receptor-inde- eluted protein retained the cytotoxic activity, the lagging
pendent cytotoxic activity by an ion channel formation peak did not show any detectable activity. The gradual
at acidic pH, most likely through the hole in the middle conversion of TRAIL trimer to inactive form is compara-
ble to TNFa that also dissociates slowly into inactiveof the trimeric structure that has an adequate size for
Immunity
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imaging-plate system mounted on a M18XHF X-ray generator oper-forms (Corti et al., 1992). Therefore, it is highly desirable
ated at 50 kV and 90 mA. Platinum derivative data set was collectedto design stable TRAIL mutants for application pur-
using an x-ray beam (l 5 1.0 AÊ ) from the BL18B beamline at theposes. It was noted that a large cavity is present at the
Photon Factory (Table 1). As described (Cha et al., 1999), initial
trimer interface of TRAIL between Tyr-183 and Cys-230 phase estimates were calculated by MR using the 1.8 AÊ structure
(Figure 5), which appears a good target site for generat- of a TNFa mutant as a search model. Due to the high content of
the loops (z46%) plus the low sequence homology, additional phaseing stable TRAIL mutants. Asn-228 is 5 AÊ apart from
information was necessary and was obtained from two heavy atomTyr-240 of an adjacent subunit. The substitution of Asn-
derivative crystals. Heavy atom binding sites were identified by dif-228 with a large hydrophobic residue could effectively
ference Fourier analysis using the phases derived from MR. The MRbe accommodated by the cavity and induce stronger
solution was modified to include b sheets and only some parts of
intersubunit interactions with Tyr-240. loops that are sufficiently well defined in simulated annealing omit
In conclusion, we have determined the structure of maps calculated by consecutively omitting 10 residues at the loop
TRAIL, a novel cytokine that specifically kills tumor cells regions each time. The heavy atom positions were used to calculate
MIR phases. The MIR phases with the two derivative data had ain vitro and in vivo without a side effect. Although the
mean figure of merit of 0.47 at 3.5 AÊ resolution and were improvedoverall fold of TRAIL is similar to that of TNFa, TNFb,
by solvent flattening and 2-fold noncrystallographic symmetry (NCS)and CD40L, particular details in local structures are sig-
density averaging. Some parts of the partial model inconsistent with
nificantly different. We have shown that the novel frame the MIR map were further truncated. A combination of the partial
insertion plays a critical role in the receptor recognition. model and the MIR phases and a 2-fold NCS averaging at 8±3.5 AÊ
By the model building, we addressed the question of resulted in a significantly improved electron density map in which
many loop regions could be traced. The MIR phasing and densityhow specific recognition between the large ligand and
modifications were carried out using the CCP4 suite (CCP4, 1994).the receptor families could be achieved. The structural
Crystallographic refinements, iterative map calculations, and modelelucidation and the structure-based mutational study
buildings were done using X-PLOR (BruÈ nger, 1992) and CCP4 suitepresented here should expedite unraveling the biologi-
(CCP4, 1994), respectively. The 2-fold NCS restraints were main-
cal functions of TRAIL and serve as a valuable frame- tained until the last refinement. From the beginning of the refinement,
work directing rational design of TRAIL mutants for ther- 5% of total reflections from the native data set were set aside for
apeutic gain. monitoring Rfree value. The final model consists of 145 amino acids
with an Rvalue of 20.9% and an Rfree of 28.2%. The model does not
contain highly disordered residues 114±120, 195±204, and 231±236Experimental Procedures
for which electron densities are lacking. Fairly weak electron densi-
ties are observed for residues 132±133, 137±140, and 157±158, andPurification and Crystallization
these regions are poorly defined.Active human TRAIL was refolded from inclusion body and purified
as described (Cha et al., 1999) from Escherichia coli strain
BL21(DE3). Later, it was found that some fraction (, 50%) of the Modeling TRAIL/sDR4 Complex
expressed TRAIL was in soluble form when the cells were grown at An initial model of sDR4 was obtained by the comparative protein-
258C. The soluble form of TRAIL can be purified by employing two modeling program SWISS-MODEL (Peitsch, 1996), using the struc-
column chromatographic steps. After running the supernatant of ture of sTNF-R55 bound to TNFb as a starting point. When this
the cell extracts on a SP sepharose Fast Flow column (Pharmacia and the TRAIL structure were superposed on the TNFb/sTNF-R55
Biotechnology), the eluted fraction was concentrated to 10 mg/ml structure, the sDR4 model showed steric conflicts mainly with the
and loaded on Superdex 200 HR 10/30 sizing column (Pharmacia b turn of the AA99 loop. The conflicts, however, were mostly removed
Biotechnology). The TRAIL fractions showed a single band on an by a rigid-body movement of a module (residues 57±71) in the sec-
SDS-PAGE gel. The soluble form of TRAIL shows the same cytotoxic ond CRD of sDR4. The connection sites between the modules in
activity as the refolded TRAIL. All the TRAIL mutants were purified sTNF-R55 are known to exhibit pronounced flexibility for the rigid-
from the soluble fraction of the cell extract. They were eluted with body movements of the modules upon changes in solvent condi-
the same retention time from the size exclusion column as the wild- tions or ligand binding (Naismith et al., 1996). The torsion angle
type TRAIL. This indicates that the mutations do not cause structural changes at the connection (Gln56) did not result in a steric clash
distortions. Crystals of refolded TRAIL were obtained using a precip- between adjacent modules. In addition to the torsion angle change,
itant solution containing 25% polyethyleneglycol monomethyl ether the sDR4 model was rotated slightly to remove collisions with the
550, 0.05 M BICINE (pH 9.0), and 10 mM CdCl2. The crystals of GH loop of TRAIL, and a brief energy minimization was performed
TRAIL are hexagonal P63, with two monomers per asymmetric unit with the program X-PLOR (BruÈ nger, 1992). CLUSTAL W sequence
and cell dimensions a 5 b 5 65.61, c 5 131.70 AÊ . Solubilized TRAIL alignment of sTNF-R55 and sDR4 is shown below on which the rigid
crystals exhibited nearly the same cytotoxic activity as the freshly body movement of modules in the sDR4 model was based. The
purified TRAIL. residues constituting the second and third CRDs in sTNF-R55 (the
first and second CRDs in sDR4) are represented by bold and shaded
Cytotoxicity Measurement letters, respectively. Each arrow bar indicates a module.
The cytotoxic activities of TRAIL and its mutants were measured
on actinomycin D±treated Jurkat T cells as described (Creasey et
al., 1987) with some modifications. Jurkat T cells were seeded just
before use at 5 3 104 cells/well into a 96-well microtiter plate in
RPMI 1640 containing 10% fetal calf serum and 0.5 mg/ml of actino-
mycin D. After addition of various concentrations of TRAIL and its
mutants, the cells were incubated in a humidified atmosphere of
5% CO2 for 20 hr at 378C. Cell viability was determined by measuring
the cellular metabolic activity with 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium bromide
assay according to the manufacturer's instructions. Percent cell
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